By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Chinese molecular diagnostics firm Amoy Diagnostics today announced the Chinese State Food and Drug Administration has approved its KRAS mutation detection kit.

The Xiamen-based firm can now market its KRAS test for clinical use in China. In a statement, AmoyDx said the KRAS kit is the first molecular diagnostic assay to receive approval in China for use in personalized clinical testing in oncology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.